- Open
- 0.65
- High
- 0.70
- Low
- 0.62
- Close
- 0.67
- Change
- -0.06 (-9.09%)
- Volume
- 582,659
| 30 Sept 2026 | 16:11:23 | Holding(s) in Company |
| 29 Sept 2026 | 07:00:06 | Half-year Financial Report |
| 22 Sept 2026 | 07:00:06 | Notice of Results |
| 28 Aug 2026 | 07:00:03 | CARDIO inCode-Score milestone clinical results |
| 18 Aug 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 10 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Genincode plc develops and commercializes genetic testing solutions aimed at assessing the risk of cardiovascular disease. The company offers a range of products, including genetic testing kits and laboratory testing services, which utilize genetic and clinical data to provide healthcare professionals with insights for patient risk assessment. Genincode operates primarily in the healthcare sector, serving hospitals, clinics, and healthcare providers, with a focus on markets in the United Kingdom and the United States.
| 30 Sept 2026 | 16:11:23 | Holding(s) in Company |
| 29 Sept 2026 | 07:00:06 | Half-year Financial Report |
| 22 Sept 2026 | 07:00:06 | Notice of Results |
| 28 Aug 2026 | 07:00:03 | CARDIO inCode-Score milestone clinical results |
| 18 Aug 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 10 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Genincode plc develops and commercializes genetic testing solutions aimed at assessing the risk of cardiovascular disease. The company offers a range of products, including genetic testing kits and laboratory testing services, which utilize genetic and clinical data to provide healthcare professionals with insights for patient risk assessment. Genincode operates primarily in the healthcare sector, serving hospitals, clinics, and healthcare providers, with a focus on markets in the United Kingdom and the United States.
| 1 Jul 2026 |
| 13:30:58 |
| Result of AGM |
| 28 Aug 2026 |
| AIM movers: Potential Meta boost for Kooth and initial resources at Motapa for Caledonia Mining |
| 28 Aug 2026 | GENinCode shares rise over 18% intraday after coronary disease test results presented at European conference |
| 28 Aug 2026 | GENinCode genetic test yields positive results in real-world heart-risk assessment pilot |
| 11 Jun 2026 | AIM movers: Record order for Concurrent Technologies and RWS profit recovers |
| 8 Jun 2026 | AIM movers: Beeks Financial contract win and Audioboom ends strategic review |
| 3 Jun 2026 | AIM Market Roundup: Marechale Capital, Genincode, Boohoo |
| 1 Jul 2026 |
| 13:30:58 |
| Result of AGM |
| 28 Aug 2026 |
| AIM movers: Potential Meta boost for Kooth and initial resources at Motapa for Caledonia Mining |
| 28 Aug 2026 | GENinCode shares rise over 18% intraday after coronary disease test results presented at European conference |
| 28 Aug 2026 | GENinCode genetic test yields positive results in real-world heart-risk assessment pilot |
| 11 Jun 2026 | AIM movers: Record order for Concurrent Technologies and RWS profit recovers |
| 8 Jun 2026 | AIM movers: Beeks Financial contract win and Audioboom ends strategic review |
| 3 Jun 2026 | AIM Market Roundup: Marechale Capital, Genincode, Boohoo |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £362m | -0.5% | |
| £16m | +0.3% | |
| £14m | -0.7% | |
GENIGenincode plc | £5m | -0.8% |
| £3m | -0.9% | |
| £2m | +0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £362m | -0.5% | |
| £16m | +0.3% | |
| £14m | -0.7% | |
GENIGenincode plc | £5m | -0.8% |
| £3m | -0.9% | |
| £2m | +0.2% |
